S. Konstantinov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Konstantinov has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
A. Kostovski
Lab. for Experimental Chemotherapy, Dept. of Pharmacology and Toxicology, Faculty of Pharmacy at the Medical University of Sofia, 2 Dunav St., 1000 Sofia, Bulgaria
1 shared publicationM. Berger
Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
1 shared publicationM. Genova
National Centre for Clinical and Transfusion Hematology, Lab. for Flow Cytometry, 6 Plovdivsko pole, 1156 Sofia, Bulgaria
1 shared publicationM. Topashka-Ancheva
Inst. of Zoology, Bulgarian Academy of Sciences, 1 Tsar Osvoboditel Blvd., 1000 Sofia, Bulgaria
1 shared publication
Latest Publications
- 1 May 2002
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 128 (5) , 271-278
Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines
Purpose: The purpose of this study was to characterise bendamustine's cytotoxic and apoptotic activity in a panel of leukemia and breast cancer cell lines in comparison to its clastogenicity in murine bone marrow. Methods: The cytotoxic effect of bendamustine was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)-dye reduction assay. Induction of apoptosis was evidenced by DNA gel electrophoresis, nuclear staining, Western blot poly-(adenosine diphosphate-ribose) polymerase (PARP) cleavage, and flow cytometry. As a measure of hematological toxicity, the formation of chromosomal aberrations was investigated in bone marrow cells isolated from mice treated with low non-toxic doses of bendamustine and lomustine. Results: Bendamustine was preferably active against leukemic cells of lymphoid origin and was found to induce apoptosis in SKW-3 and BV-173 cells as shown by oligonucleosomal DNA and nuclear fragmentation, PARP cleavage, and formation of a sub-G1 fraction. Myeloid and breast carcinoma cell lines were resistant towards bendamustine with the exception of HL-60 cells which exhibit an intermediate sensitivity. Bendamustine was found to have a very low clastogenic effect as compared with equimolar doses of lomustine. Conclusion: Taken together, the mode of action of bendamustine includes induction of apoptosis. The specific spectrum of activity and the unexpectedly low clastogenicity support the hypothesis that bendamustine in not a typical alkylating agent but exerts an additional mode of action, possibly as a purine antimetabolite.
- 1 May 2002
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 128 (5) , 271-278
Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines
Purpose: The purpose of this study was to characterise bendamustine's cytotoxic and apoptotic activity in a panel of leukemia and breast cancer cell lines in comparison to its clastogenicity in murine bone marrow. Methods: The cytotoxic effect of bendamustine was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)-dye reduction assay. Induction of apoptosis was evidenced by DNA gel electrophoresis, nuclear staining, Western blot poly-(adenosine diphosphate-ribose) polymerase (PARP) cleavage, and flow cytometry. As a measure of hematological toxicity, the formation of chromosomal aberrations was investigated in bone marrow cells isolated from mice treated with low non-toxic doses of bendamustine and lomustine. Results: Bendamustine was preferably active against leukemic cells of lymphoid origin and was found to induce apoptosis in SKW-3 and BV-173 cells as shown by oligonucleosomal DNA and nuclear fragmentation, PARP cleavage, and formation of a sub-G1 fraction. Myeloid and breast carcinoma cell lines were resistant towards bendamustine with the exception of HL-60 cells which exhibit an intermediate sensitivity. Bendamustine was found to have a very low clastogenic effect as compared with equimolar doses of lomustine. Conclusion: Taken together, the mode of action of bendamustine includes induction of apoptosis. The specific spectrum of activity and the unexpectedly low clastogenicity support the hypothesis that bendamustine in not a typical alkylating agent but exerts an additional mode of action, possibly as a purine antimetabolite.